- Open Access
Cohesin is required for expression of the estrogen receptor-alpha (ESR1) gene
Epigenetics & Chromatinvolume 5, Article number: 13 (2012)
In conjunction with posttranslational chromatin modifications, proper arrangement of higher order chromatin structure appears to be important for controlling transcription in the nucleus. Recent genome-wide studies have shown that the Estrogen Receptor-alpha (ERα), encoded by the ESR1 gene, nucleates tissue-specific long-range chromosomal interactions in collaboration with the cohesin complex. Furthermore, the Mediator complex not only regulates ERα activity, but also interacts with the cohesin complex to facilitate long-range chromosomal interactions. However, whether the cohesin and Mediator complexes function together to contribute to estrogen-regulated gene transcription remains unknown.
In this study we show that depletion of the cohesin subunit SMC3 or the Mediator subunit MED12 significantly impairs the ERα-regulated transcriptome. Surprisingly, SMC3 depletion appears to elicit this effect indirectly by rapidly decreasing ESR1 transcription and ERα protein levels. Moreover, we provide evidence that both SMC3 and MED12 colocalize on the ESR1 gene and are mutually required for their own occupancy as well as for RNAPII occupancy across the ESR1 gene. Finally, we show that extended proteasome inhibition decreases the mRNA expression of cohesin subunits which accompanies a decrease in ESR1 mRNA and ERα protein levels as well as estrogen-regulated transcription.
These results identify the ESR1 gene as a cohesin/Mediator-dependent gene and indicate that this regulation may potentially be exploited for the treatment of estrogen-dependent breast cancer.
Transcriptional control is a highly ordered and complex process involving interactions between various transcription factors and the transcriptional apparatus. Importantly, changes in chromatin organization, including post-translational histone modifications and higher order chromatin structure direct transcriptional activity and control gene expression patterns[2, 3]. Recent studies have begun to uncover the complexity of interactions between different chromatin loci on a genome-wide level[4–6].
The estrogen receptor-alpha (ERα) is a ligand-activated transcription factor which plays an essential role in directing tissue-specific gene expression. Importantly, ERα is a primary target for anti-estrogen therapy in breast cancer and its presence is a prognostic marker for patient outcome[7, 8]. Interfering with distinct aspects of ERα-regulated transcription may provide novel therapeutic options for the treatment of ERα-positive breast cancer. During gene transcription ERα functions not only to recruit an intricate network of transcriptional coregulators, but also nucleates long-range chromosomal interactions. These functions are important for directing cell type-specific transcriptional programs.
Long-range chromosomal interactions appear to be stabilized by the cohesin complex. In mammals, the cohesin complex consists of a ring structure containing SMC1A and SMC3 which is held together by the proteins RAD21 and STAG1/STAG2. Cohesin plays a central role in sister chromatid cohesion during and following DNA replication. Consistently, mutations in the cohesin complex have been found in different types of cancer and have been linked to aneuploidy[12, 13]. Interestingly, mutations in the Nipped-B-like (NIPBL) gene[14–16], which loads the cohesin complex onto chromatin, or mutations in SMC1A or SMC3[17–19] lead to a developmental phenotype called Cornelia de Lange Syndrome (CdLS). In addition to developmental phenotypes such as delayed neurodevelopment and other structural abnormalities, CdLS patients frequently exhibit potential endocrine-related defects such as slower pubertal growth and irregular menstrual cycles. Consistent with a potential particular importance of cohesin in endocrine-regulated processes, cohesin subunits have been implicated in transcriptional regulation by some nuclear hormone receptors in both mammalian cells and in Drosophila[4, 10, 21–24]. Furthermore, a number of studies indicate that the phenotypes observed in CdLS patients are likely not due to defects in sister chromatid cohesion, but rather to changes in transcription[25, 26].
Mediator is a large multisubunit complex which interacts directly with a number of transcription factors to facilitate RNA Polymerase II (RNAPII) recruitment to target genes. Recent studies indicated that Mediator also interacts with cohesin to control long-range chromosomal interactions in embryonic stem cells. Given the important role of Mediator in controlling ERα function[29–31] and the potential importance of cohesin in controlling ERα-nucleated long-range chromosomal interactions[4, 10], we hypothesized that these complexes may similarly control estrogen-regulated gene expression. Our results show that depletion of components of either the cohesin or Mediator complexes significantly impairs ERα-regulated gene transcription. Surprisingly, this effect appears to be due to decreased transcription of the ESR1 gene following SMC3 knockdown. These effects could be mimicked by prolonged treatment with the clinically utilized proteasome inhibitor bortezomib which also decreased the mRNA levels of ESR1 and several cohesin subunits as well as SMC3 and ERα protein levels. These results provide an important molecular insight into the possible clinical benefit of proteasome inhibitor treatment for estrogen-dependent breast cancer and may also explain potential endocrine phenotypes frequently observed in patients with CdLS.
SMC3 and MED12 knockdown decrease ERα-dependent transcription
In order to determine whether cohesin and Mediator are both required for estrogen-regulated transcription, we performed siRNA-mediated knockdown studies of both SMC3 and MED12 in MCF7 breast cancer cells. We investigated the expression of the CXCL12, GREB1, PGR and PKIB genes which we previously identified as robust estrogen-regulated genes in transcriptome-wide studies and which all demonstrate occupancy of cohesin components and ER/cohesin-based chromosomal looping[4, 10, 32]. As shown in Figure 1A (and Figure 1A in Additional file1), depletion of SMC3, MED12 or RAD21 significantly decreased the estrogen-induced mRNA levels of each of the estrogen-regulated genes tested. Notably, SMC3 knockdown also decreased the basal expression of these estrogen-regulated genes even in the absence of estrogen. These effects are reminiscent of those observed upon treatment with the pure anti-estrogen ICI 182,780, where both estrogen-induced and basal expression of estrogen responsive genes is affected by anti-estrogen treatment. Thus, both basal and estrogen-induced expression of estrogen target genes appears to be dependent upon cohesin and Mediator for its activity. In contrast, SMC3 and MED12 mRNA expression was unaffected by either estrogen treatment or knockdown of the other component (Figure 1B).
To further examine the extent of the effects of SMC3 and MED12 knockdown on ERα activity, we performed transcriptome-wide analyses comparing the effects of each individual knockdown on the transcriptional profile of MCF7 cells both in the presence and absence of estrogen. As shown in Figure 2A, SMC3 depletion significantly blocked the overwhelming majority of estrogen-regulated gene transcription in MCF7 cells (compare Figure 2A left and right columns). Moreover, consistent with the single gene studies in Figure 1A, even the basal levels of expression were significantly affected (middle column). This effect was not limited to transcriptional activation since estrogen-repressed gene transcription was also reversed. A similar, albeit somewhat weaker, effect was also observed for MED12 knockdown (Figure 2B).
Cohesin or mediator knockdown impairs ESR1 gene expression
Unexpectedly, in the process of bioinformatic analysis of these transcriptome data, we found ESR1 mRNA levels were also SMC3-dependent. We therefore performed time course analyses of RNA (Figure 3A) and protein (Figure 3B) expression to determine the kinetics of SMC3 and ESR1 regulation upon SMC3 depletion. These studies revealed a very rapid and parallel downregulation of SMC3 and ESR1 RNA levels already at 12 h after transfection of SMC3 siRNA (Figure 3A). Similarly, RAD21 knockdown also decreased ESR1 mRNA levels as well (Figure 1B in Additional file1). ERα protein levels were also decreased following knockdown of either SMC3 or MED12 (Figure 3B). Surprisingly, despite their reported long half-lives, both SMC3 and ERα protein levels were similarly decreased already 12 h post-transfection (Figure 3C). Thus, ESR1 expression is highly dependent upon cohesin and Mediator.
SMC3 and MED12 are required for mutual occupancy and transcription across the ESR1 gene
Previous chromatin immunoprecipitation-sequencing (ChIP-seq) studies revealed cohesin binding sites genome-wide in both the presence and absence of estrogen in MCF7 cells. Analysis of these data revealed a number of cohesin binding sites on the ESR1 gene (Figure 4A). We therefore performed ChIP analyses to verify cohesin binding to the ESR1 gene. As shown in Figure 4B, SMC3 was present at both of the investigated cohesin binding sites, but at much lower levels near the transcriptional start site (TSS) or 3′ end of the ESR1 gene. Importantly, SMC3 occupancy was decreased by either SMC3 or MED12 knockdown.
Consistent with a cooperative function with SMC3, MED12 was also present at both cohesin binding sites (Figure 4C). In addition, it was also found in significant levels at the TSS, but not at the 3′ end. This finding is consistent with the important role of the Mediator complex in transcriptional initiation.
To determine the effects of SMC3 and MED12 depletion on RNAPII-dependent ESR1 transcription, we also investigated the occupancy of both total and elongating RNAPII (phosphorylated at Ser2 of the heptapeptide repeat in the C-terminal domain). Consistent with the decreased ESR1 mRNA levels observed in Figure 3A, total RNAPII levels were decreased at the TSS and 3′ end of the ESR1 gene after SMC3 or MED12 siRNA transfection (Figure 4D). However, significant levels of RNAPII were still present even after depletion of SMC3 or MED12 depletion. The effects of SMC3 or MED12 were more apparent when investigating the effects on elongating RNAPII. Surprisingly, while P-Ser2 RNAPII is generally enriched at higher levels in the transcribed region and 3′ end of active genes, significant levels were observed at both ends of the ESR1 gene. These results are similar to that observed for other genes, which demonstrated similar or higher levels of P-Ser2 RNAPII at the TSS compared to the transcribed region. Importantly, the levels of P-Ser2 RNAPII were reduced to background levels at both the TSS and 3′ end in the absence of either SMC3 or MED12 (Figure 4E). Thus, the knockdown of components of either the cohesin or Mediator complexes may affect both transcriptional initiation as well as elongation.
Bortezomib decreases SMC3 and ESR1 gene expression
In a previous study we showed that short-term (2 h) treatment with the clinically utilized proteasome inhibitor bortezomib had no effect on ERα recruitment to target gene expression. However, another study demonstrated that chronic treatment with bortezomib decreased ESR1 mRNA and ERα protein levels. Therefore, we also tested the effects of bortezomib treatment on estrogen-regulated gene expression in this system. Indeed, bortezomib treatment for 6 h significantly decreased the estrogen-induced mRNA levels of CXCL12, PGR, GREB1 and PKIB (Figure 5A). These results paralleled a decrease in estrogen-induced long-range chromosomal interactions on both the CXCL12 and GREB1 genes (Figure 5B).
To verify the effects of bortezomib treatment on ESR1 expression and to test whether a similar effect could be observed for cohesin and/or Mediator subunits, we examined ESR1, MED12 and cohesin subunit mRNA levels at various time points following bortezomib treatment. As shown in Figure 6A, ESR1 and SMC3 showed similar profiles with the mRNA levels of both being unaffected at 2 h and greater effects at 6 and 24 h after treatment. Similar effects were also observed for STAG1 and RAD21, and to a lesser extent SMC1A, whose mRNA levels also decreased following extended bortezomib treatment, albeit to differing degrees. In contrast, MED12 mRNA levels were only mildly and transiently affected by bortezomib treatment. The effects on cohesin and ERα were also substantiated at the protein levels where bortezomib treatment resulted in decreased SMC3 and ERα protein levels (Figure 6B). In contrast, as previously reported, estrogen treatment alone also decreased ERα protein levels without affecting SMC3 levels.
ESR1 and SMC3 regulation is not due to a cell cycle arrest
Given its essential role in cell cycle progression, it was conceivable that the changes observed in SMC3 (and consequently also ESR1) gene expression upon bortezomib treatment (or cohesin knockdown) may be due to a general effect caused by a cell cycle arrest. Interestingly, while cohesin activity is required for sister chromatin cohesion, knockdown of either SMC3 or MED12 and further growth under hormone-free conditions resulted in a slight increase in the G1 fraction of cells compared to control transfected cells (Figure 2 in Additional file1). In order to test whether the gene expression effects we observed were due to a G1 cell cycle arrest, we induced a G1 arrest by growing cells under serum-free conditions. Although this treatment substantially increased the G1 fraction of cells (Figure 7A), serum withdrawal had no effect on either SMC3 or ESR1 mRNA or protein levels (Figure 7B and C).
Genome organization within the nucleus is emerging as one of the most exciting, but highly complex gene expression regulatory mechanisms. The recent development of new laboratory techniques and the advent of next generation sequencing technologies have made it possible to analyze intra- and inter-chromosomal interactions on a genome-wide level. Despite these advances much still remains to be learned about the extensive network of proteins controlling genome organization and the plasticity of its regulation.
In this study we sought to determine the role of the cohesin and Mediator complexes in controlling estrogen-dependent gene transcription. While we saw a substantial reversal in the estrogen-regulated gene expression pattern following depletion of components of each complex, these effects may be an indirect effect caused by decreased ESR1 expression. Consistently, both SMC3 and MED12 protein binding was detected on the ESR1 gene and depletion of either component not only affected their occupancy, but also RNAPII occupancy on the ESR1 gene. Thus, these data imply that a specific Mediator/cohesin-directed higher order chromatin structure is essential for proper ESR1 expression. In the course of this study a number of possible interactions between various cohesin binding sites on the ESR1 gene were tested by chromatin conformation capture analyses. Unfortunately, interactions between the investigated sites could not be observed (data not shown). This finding is consistent with recent data demonstrating that many long-range chromosomal interactions do not necessarily occur between adjacent cohesin binding sites but rather often encompass chromosomal loops of several hundred kilobases. Thus it is currently impossible to precisely predict which cohesin binding sites and which chromatin interactions are essential for directing proper ESR1 gene transcription. Additional studies in MCF7 cells using cohesin components for genome-wide chromosomal interaction analyses, similar to those recently reported for CTCF in embryonic stem cells, may help to uncover these interactions. Furthermore, additional non-looping functions of cohesin (for example, through direct interaction with other transcriptional regulatory proteins) cannot be excluded and must be considered.
Previous studies indicated a critical role for cohesin components in controlling ERα-regulated gene transcription[4, 10]. Although cohesin likely plays a direct role in ERα-directed transcription, the finding that the expression of the ESR1 gene itself is directly controlled by the cohesin complex suggests that caution will also need to be used when interpreting other siRNA-mediated knockdown studies of cohesin complex components. Similar effects were also recently observed when investigating the effects of cohesin on ecdysone receptor-regulated transcription[23, 24]. One potential aspect which may affect the results in many studies is the cell cycle-dependent effects of cohesin knockdown. Given the important role of cohesin in sister chromatid cohesion, a knockdown of cohesin complex components will affect cell cycle progression. As previously reported and demonstrated in our results, given the cell cycle arrest induced by estrogen withdrawal, this aspect likely does not influence the interpretation of our data. However, the molecular mechanism leading to the reported defect in estrogen-induced S-phase entry following depletion of the cohesin complex component RAD21 may need to be reassessed. In this case, the effects observed may not be due to defects in the induction of ERα-directed chromosomal interactions, but rather due to an upstream loss of ESR1 gene expression. Given the complexity of the role of different chromosomal interactions and the dramatic changes in transcriptional regulation that occur following cohesin complex component depletion, a number of secondary effects such as those observed in our study may occur. Furthermore, depletion of the cohesin complex will likely result not only in the loss of chromosomal loops that promote gene transcription (by bringing enhancers close to genes), but also loops which repress gene transcription (for example, cohesin binding sites which serve as insulators). The net effect of cohesin depletion will be a complex mixture of all of these effects.
One important aspect of these findings is their potential implication for the treatment of ERα-positive breast cancer. We confirmed the findings of another study which clearly demonstrated that chronic bortezomib treatment decreases both ESR1 mRNA and ERα protein levels. Although the effects of proteasome inhibition are highly pleiotropic, the finding that bortezomib treatment leads to a rapid and parallel decrease in both SMC3 and ESR1 gene expression opens an interesting new possible mechanism for its potential utility in the treatment of ERα-positive breast cancer. Although studies using bortezomib as a single agent to treat breast cancer were disappointing, new clinical studies are currently underway in which bortezomib is being tested in combination with a pure anti-estrogen specifically in ERα-positive metastatic breast cancer (NCT01142401). Given the results presented here, it would be particularly interesting to investigate ERα expression in patients receiving bortezomib treatment to determine if this effect is also observed in vivo. Given the potential role of cohesin downstream of the androgen receptor[21, 22], combined anti-androgen and bortezomib treatment may also prove to be effective in combatting androgen-dependent prostate cancer.
Analogous to the effects of bortezomib treatment, other therapies may work by a similar epigenomic mechanism to decrease ESR1 expression. For example, treatment of MCF7 cells with several different histone deacetylase inhibitors (HDACi) also resulted in decreased ESR1 expression and a concomitant decrease in estrogen-regulated transcription. Interestingly, although it is currently unknown whether HDACi treatment affects SMC3 expression, the proteasomal subunit PSMB2 is downregulated following HDAC inhibition. Given the similar effects observed between proteasome inhibition and proteasome subunit knockdown, it is possible that the effects of HDACi treatment on ESR1 expression may also occur as a secondary effect through downregulation of SMC3 expression. Future studies will need to address whether the decrease in ERα levels following proteasome or HDAC inhibition has a positive or negative effect on tumorigenesis. While decreased ESR1 expression may initially decrease tumor growth, it is possible that these treatments may, in fact, enhance the formation of more aggressive ERα-negative tumors.
Finally, the finding that ESR1 expression is strongly dependent upon the integrity of the cohesin complex may also provide an insight into the molecular mechanisms behind various developmental phenotypes observed in CdLS. The question of whether NIPBL, SMC1A or SMC3 mutation lead to decreased ERα levels in CdLS patients will need to be further addressed. Similarly, whether proteasome or HDAC inhibition lead to decreased ERα expression in patients, and how this leads to various side effects (that is, related to fertility) should also be investigated.
Based on the results presented here, we propose that the ESR1 gene is an important transcriptional target of cohesin and Mediator which is particularly sensitive to changes in the integrity of these complexes. It also uncovers a molecular mechanism and potential clinical utility for various therapies which alter ESR1 expression as a secondary effect following changes in SMC3 expression. Additional clinical studies, as well as cell culture and mouse model studies, will help to determine the clinical efficacy of these therapeutic strategies and their efficacy in the treatment of breast cancer.
Cell culture and RNA interference
MCF7 cells were obtained from the Department of Tumor Biology at the University Medical Center Hamburg-Eppendorf (Hamburg, Germany) and were grown in phenol red–free high-glucose DMEM (Invitrogen; Carlsbad, California, USA) supplemented with 10% bovine growth serum (Thermo Scientific; Waltham, MA, USA). MCF7 cells were grown in DMEM containing 5% charcoal-dextran–treated FBS (CSS; HyClone : Thermo Scientific, MA, USA) 1 to 2 days prior to treatment with 10 nmol/L 17-β-estradiol (Sigma-Aldrich; Missouri, USA) as indicated. Where indicated, cells were treated with 50 nmol/L bortezomib (LC Laboratories; Woburn, USA). Small interfering RNAs for SMC3 (Dharmacon; Thermo Scientific, USA; M-006834-01-0005), MED12 (Ambion; Invitrogen, USA; a pool of s19362, s19363 and s19364), or a negative control siRNA (Dharmacon; D-001206-13) were transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions. Flow cytometry experiments were performed as previously described.
Antibodies and western blot
Antibodies for western blot and/or ChIP analyses were beta-actin (Abcam; Cambridge, UK; ab6278), ERα (Santa Cruz; CA, USA sc-543), non-specific IgG (Abcam; ab46540), MED12 (Bethyl; TX, USA ; ICH-00180), RNAPII (sc-899), Ser2-phosphorylated RNAPII CTD, and SMC3 (Abcam; ab9263). For Western blot analyses, cells were lysed in RIPA buffer containing 1 mM Pefabloc and 1 ng/μl aprotinin/leupeptin, separated by SDS-PAGE and transferred to a nitrocellulose membrane. Proteins were detected using the respective antibodies by enhanced chemiluminescence.
Microarray and gene expression analysis
Total RNA was isolated from cells using the Qiazol reagent (Qiagen; Hilden, Germany) according to the manufacturer’s instructions. One microgram of total RNA was reverse transcribed using random nonamers (Metabion; Martinsried, Germany). Real-time PCR analysis was performed as previously described using the following primers: CXCL12 (forward: 5′-TGCCAGAGCCAACGTCAAGCATC-3′; reverse: 5′-CGGGTCAATGCACACTTGTCTGTTGT-3′), ESR1 (forward: 5′-GCATTCTACAGGCCAAATTCA-3′; reverse: 5′-TCCTTGGCAGATTCCATAGC-3′), GREB1 (forward: 5′-GTGGTAGCCGAGTGGACAAT-3′; reverse: 5′-ATTTGTTTCCAGCCCTCCTT-3′), 28S rRNA (forward: 5′-CTTTAAATGGGTAAGAAGCC-3′ ; reverse: 5′-ATCAACCAACACCTTTTCTG-3′), MED12 (forward: 5′-ACAGGCTCCCATGCTGACGGA-3′; reverse: 5′-AAGGCAAGGTCCCCTCGGGAG-3′), PGR (forward: 5′-TCCACCCCGGTCGCTGTAGG-3′; reverse: 5′-TAGAGCGGGCGGCTGGAAGT-3′), PKIB (forward: 5′-ACGTGGAGTCTGGGGTCGCC-3′; reverse: 5′-GAGAGCCTCCAGTTTGAGGGGCA-3′), and SMC3 (forward: 5′-GTTTCAACCCAGCTGGCCCGTG-3′; reverse: 5′-CGATGGCTGACTTGGTCACCTTCCA-3′). Gene expression was normalized to a control gene (28S rRNA) and expressed as fold induction relative to the untransfected, control condition. For whole transcriptome analyses, microarray studies were performed by the Vancouver Prostate Centre Laboratory for Advanced Genome Analysis (Vancouver, Canada) using the Illumina human HT-12 v4 beadchip. Gene expression data were analyzed as previously described (Prenzel et al., 2011). Heatmaps indicate genes which were at least 1.5-fold up- or downregulated with P-values ≤ 0.05. All gene expression data has been deposited into the GEO repository [accession number GSE38252].
Chromatin immunoprecipitation and chromosome conformation capture assays
Chromatin immunoprecipitation was performed and analyzed by quantitative real-time PCR as previously described using the following primers for various positions along the ESR1 gene: TSS (forward: 5′-AAGTTGGAGGCCCGGGAGCC-3′; reverse: 5′-CCCGACGGGAGCAAGTGCAG-3′), cohesin binding site 1 (forward: 5′-CACGCTGGCTACATTTCAAGTGCTTCA-3′; reverse: 5′-AGTGCTGCCATCTACAGGGTCGAC-3′), cohesin binding site 2 (forward: 5′-AAACAGGCAGCACGCAGTGTTTCT-3′; reverse: 5′-GTGATTGAGCTCTTGTGGCTTCTTGGG-3′), 3′ end (forward: 5′-CCCCAGAGGCCGAGTGCCA-3′; reverse: 5′-CCTGCCTGGAAAGGTGACATGTGTG-3′). ChIP DNA samples were normalized to input DNA from the same sample and expressed as percent input. Chromatin conformation capture studies were performed as described previously using the following primer/probe combinations: CXCL12 positive interaction (forward: 5′-GAAGGAAGAAGAAACATGGACTCTGCTCCA-3′; reverse: 5′-ACAGAAGCTGGTTTACCGACTTGTCTGT-3′; internal probe: 5′-Fam-GCCCCAGGGCACAACACACC-BHQ1-3′), CXCL12 negative control (forward: 5′-GAAGGAAGAAGAAACATGGACTCTGCTCCA-3′; reverse: 5′-CTCCCAGTGCAGAGGGAAGCATGT-3′; internal probe: 5′-Fam-GCCCCAGGGCACAACACACC-BHQ1-3′), GREB1 positive interaction (forward: 5′-CTGGGCCTCTCCAGGGGGTTTT-3′; reverse: 5′- CCGCTGGTCAGCCGTTCAGG −3′; internal probe: 5′-Fam-GTCAGGGCAAAGGACATGGCCAG-BHQ1-3′), GREB1 negative control (forward: 5′-GCCACTACATCCTTGGCTTTGTCCAC-3′; reverse: 5′- CCGCTGGTCAGCCGTTCAGG-3′; internal probe: 5′-Fam- GTCAGGGCAAAGGACATGGCCAG-BHQ1-3′), normalization control (within the GREB1 gene) (forward: 5′-GGGCTGGGTGCCCGTTTTGT-3’; reverse: 5′-CCAGCAGCTGCACGCCACAT-3’; internal probe: 5′-Fam-CCTGTGACATCTCTCCCAGCCCC-BHQ1-3’). All interactions were quantified by real-time PCR using standard curves containing digested and re-ligated DNA from BAC clones (ImaGenes; Berlin, Germany) covering the investigated regions of the CXCL12 (RP-13309I17) and GREB1 (RPCIB753E0150Q) genes and normalized using a probe-primer pair detecting an amplicon between BtgI sites as described previously.
Cornelia de Lange Syndrome
Estrogen receptor 1
False discovery rate
Histone deacetylase inhibitor
Mediator complex subunit 12
Quantitative real-time reverse transcription polymerase chain reaction
RNA Polymerase II
Small interfering ribonucleic acid
Structural maintenance of chromosomes 3
Transcriptional start site.
Metivier R, Reid G, Gannon F: Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep. 2006, 7: 161-167. 10.1038/sj.embor.7400626.
Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell. 2007, 128: 669-681. 10.1016/j.cell.2007.01.033.
Margueron R, Reinberg D: Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet. 2010, 11: 285-296. 10.1038/nrg2752.
Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK: An oestrogen-receptor-alpha-bound human chromatin interactome. Nature. 2009, 462: 58-64. 10.1038/nature08497.
Handoko L, Xu H, Li G, Ngan CY, Chew E, Schnapp M, Lee CW, Ye C, Ping JL, Mulawadi F, Mulawadi F, Wong E, Sheng J, Zhang Y, Poh T, Chan CS, Kunarso G, Shahab A, Bourque G, Cacheux-Rataboul V, Sung WK, Ruan Y, Wei CL: CTCF-mediated functional chromatin interactome in pluripotent cells. Nat Genet. 2011, 43: 630-638. 10.1038/ng.857.
Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein B, Bender MA, Groudine M, Gnirke A, Stamatoyannopoulos J, Mirny LA, Lander ES, Dekker J: Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009, 326: 289-293. 10.1126/science.1181369.
Deroo BJ, Korach KS: Estrogen receptors and human disease. J Clin Invest. 2006, 116: 561-570. 10.1172/JCI27987.
Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002, 2: 101-112. 10.1038/nrc721.
Johnsen SA, Kangaspeska S, Reid G, Gannon F: Interfering with the dynamics of estrogen receptor-regulated transcription. Ernst Schering Found Symp Proc. 2007, 2006: 1-12.
Schmidt D, Schwalie PC, Ross-Innes CS, Hurtado A, Brown GD, Carroll JS, Flicek P, Odom DT: A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res. 2010, 20: 578-588. 10.1101/gr.100479.109.
Wood AJ, Severson AF, Meyer BJ: Condensin and cohesin complexity: the expanding repertoire of functions. Nat Rev Genet. 2010, 11: 391-404.
Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D, Barrett I, Nouhi Y, Spencer F, Markowitz S, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C, Hieter P: Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA. 2008, 105: 3443-3448. 10.1073/pnas.0712384105.
Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T: Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011, 333: 1039-1043. 10.1126/science.1203619.
Gillis LA, McCallum J, Kaur M, DeScipio C, Yaeger D, Mariani A, Kline AD, Li HH, Devoto M, Jackson LG, Krantz ID: NIPBL mutational analysis in 120 individuals with Cornelia de Lange syndrome and evaluation of genotype-phenotype correlations. Am J Hum Genet. 2004, 75: 610-623. 10.1086/424698.
Krantz ID, McCallum J, DeScipio C, Kaur M, Gillis LA, Yaeger D, Jukofsky L, Wasserman N, Bottani A, Morris CA, Nowaczyk MJ, Toriello H, Bamshad MJ, Carey JC, Rappaport E, Kawauchi S, Lander AD, Calof AL, Li HH, Devoto M, Jackson LG: Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. Nat Genet. 2004, 36: 631-635. 10.1038/ng1364.
Tonkin ET, Wang TJ, Lisgo S, Bamshad MJ, Strachan T: NIPBL, encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in Cornelia de Lange syndrome. Nat Genet. 2004, 36: 636-641. 10.1038/ng1363.
Deardorff MA, Kaur M, Yaeger D, Rampuria A, Korolev S, Pie J, Gil-Rodriguez C, Arnedo M, Loeys B, Kline AD, Wilson M, Lillquist K, Siu V, Ramos FJ, Musio A, Jackson LS, Dorsett D, Krantz ID: Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with predominant mental retardation. Am J Hum Genet. 2007, 80: 485-494. 10.1086/511888.
Musio A, Selicorni A, Focarelli ML, Gervasini C, Milani D, Russo S, Vezzoni P, Larizza L: X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. Nat Genet. 2006, 38: 528-530. 10.1038/ng1779.
Pie J, Gil-Rodriguez MC, Ciero M, Lopez-Vinas E, Ribate MP, Arnedo M, Deardorff MA, Puisac B, Legarreta J, de Karam JC, Rubio E, Bueno I, Baldellou A, Calvo MT, Casals N, Olivares JL, Losada A, Hegardt FG, Krantz ID, Gómez-Puertas P, Ramos FJ: Mutations and variants in the cohesion factor genes NIPBL, SMC1A, and SMC3 in a cohort of 30 unrelated patients with Cornelia de Lange syndrome. Am J Med Genet A. 2010, 152A: 924-929. 10.1002/ajmg.a.33348.
Kline AD, Grados M, Sponseller P, Levy HP, Blagowidow N, Schoedel C, Rampolla J, Clemens DK, Krantz I, Kimball A, Pichard C, Tuchman D: Natural history of aging in Cornelia de Lange syndrome. Am J Med Genet C Semin Med Genet. 2007, 145C: 248-260. 10.1002/ajmg.c.30137.
Geck P, Maffini MV, Szelei J, Sonnenschein C, Soto AM: Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci U S A. 2000, 97: 10185-10190. 10.1073/pnas.97.18.10185.
Murthy S, Agoulnik IU, Weigel NL: Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005, 64: 362-372. 10.1002/pros.20251.
Pauli A, van Bemmel JG, Oliveira RA, Itoh T, Shirahige K, van SB, Nasmyth K: A direct role for cohesin in gene regulation and ecdysone response in Drosophila salivary glands. Curr Biol. 2010, 20: 1787-1798. 10.1016/j.cub.2010.09.006.
Schuldiner O, Berdnik D, Levy JM, Wu JS, Luginbuhl D, Gontang AC, Luo L: piggyBac-based mosaic screen identifies a postmitotic function for cohesin in regulating developmental axon pruning. Dev Cell. 2008, 14: 227-238. 10.1016/j.devcel.2007.11.001.
Dorsett D: Cohesin: genomic insights into controlling gene transcription and development. Curr Opin Genet Dev. 2011, 21: 199-206. 10.1016/j.gde.2011.01.018.
Wendt KS, Peters JM: How cohesin and CTCF cooperate in regulating gene expression. Chromosome Res. 2009, 17: 201-214. 10.1007/s10577-008-9017-7.
Malik S, Roeder RG: The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet. 2010, 11: 761-772. 10.1038/nrg2901.
Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier CC, Goossens J, Rahl PB, Levine SS, Taatjes DJ, Dekker J, Young RA: Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010, 467: 430-435. 10.1038/nature09380.
Jiang P, Hu Q, Ito M, Meyer S, Waltz S, Khan S, Roeder RG, Zhang X: Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc Natl Acad Sci USA. 2010, 107: 6765-6770. 10.1073/pnas.1001814107.
Kang YK, Guermah M, Yuan CX, Roeder RG: The TRAP/mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc Natl Acad Sci USA. 2002, 99: 2642-2647. 10.1073/pnas.261715899.
Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chait BT, Roeder RG: MED1/TRAP220 exists predominantly in a TRAP/ mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell. 2005, 19: 89-100. 10.1016/j.molcel.2005.05.015.
Prenzel T, Begus-Nahrmann Y, Kramer F, Hennion M, Hsu C, Gorsler T, Hintermair C, Eick D, Kremmer E, Simons M, Beissbarth T, Johnsen SA: Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 2011, 71: 5739-5753. 10.1158/0008-5472.CAN-11-1896.
Wardell SE, Kazmin D, McDonnell DP: Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol. 2012, 26: 1235-1248. 10.1210/me.2012-1031.
Kininis M, Isaacs GD, Core LJ, Hah N, Kraus WL: Postrecruitment regulation of RNA polymerase II directs rapid signaling responses at the promoters of estrogen target genes. Mol Cell Biol. 2009, 29: 1123-1133. 10.1128/MCB.00841-08.
Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET: Proteasome inhibition represses ERalpha gene expression in ER + cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene. 2010, 29: 1509-1518. 10.1038/onc.2009.434.
Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999, 96: 1858-1862. 10.1073/pnas.96.5.1858.
Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M: Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006, 17: 813-817. 10.1093/annonc/mdj131.
Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, Gannon F: Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene. 2005, 24: 4894-4907. 10.1038/sj.onc.1208662.
Pirngruber J, Johnsen SA: Induced G1 cell-cycle arrest controls replication-dependent histone mRNA 3′ end processing through p21, NPAT and CDK9. Oncogene. 2010, 29: 2853-2863. 10.1038/onc.2010.42.
Chapman RD, Heidemann M, Albert TK, Mailhammer R, Flatley A, Meisterernst M, Kremmer E, Eick D: Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. Science. 2007, 318: 1780-1782. 10.1126/science.1145977.
The authors would like to thank S Le Bihan and A Haegert for performing microarray experiments; D Eick and E Kremmer for providing the anti-P-Ser2 RNAPII CTD antibody 3E10; and all the members of the Johnsen group for helpful discussions. This work was funded by the German Research Foundation (DFG) Research Group 942 to TB; and the Deutsche Krebshilfe (109088) to SAJ.
The authors declare that they have no competing interests.
TP and SAJ designed the experiments. TP, UB and SN performed the experiments. FK and TB performed bioinformatic analyses of the microarray data. SJ wrote the manuscript. All authors read and approve the final manuscript.
Electronic supplementary material
Additional file 1: Figure S1. RAD21 depletion significantly reduces the estrogen-induced expression of ERα target genes. MCF7 cells transfected with control or RAD21 siRNA were grown in normal growth medium for 24 h and then for another 42 h in hormone-depleted medium before treating with 10 nM 17β-Estradiol (E2) for 6 h as indicated. Total mRNA was extracted, reverse-transcribed and analyzed by quantitative real-time PCR (qRT-PCR). (A) The expression levels of the estrogen-regulated genes CXCL12, GREB1, PGR, and PKIB were normalized to 28S ribosomal mRNA, graphed relative to the control sample and expressed as relative mRNA expression; mean values + SD, n = 2. (B) Efficient knockdown of RAD21 and its effects on ESR1 mRNA levels was verified by qRT-PCR in the same samples used in (A). RAD21 and ESR1 were normalized and expressed as in (A). Mean values + SD, n = 2. Figure S2. SMC3 or MED12 knockdown enhance hormone-withdrawal induced G1 cell cycle arrest. MCF7 cells transfected with control, SMC3 or MED12 siRNA were grown in normal growth medium for 24 h and then for another 42 h in hormone-depleted medium before flow cytometric analyses. Shown are representative profiles and the respective quantitation for duplicate samples (± SD). (PDF 108 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.